Prevention Of Drug-Induced Osteonecrosis Of The Jaw In Cancer Patients
Open Access
- 15 July 2022
- journal article
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 12 (2) , 151-158
Abstract
The occurrence of drug-induced osteonecrosis of the jaw in cancer patients treated using bone-modifying medications (bisphosphonates and denosumab) is a highly relevant research problem studied by dentists, maxillofacial surgeons, and oncologists. Despite the large number of publications, practical approaches to preventing drug-induced osteonecrosis of the jaw remain to be developed, which is confirmed by the increasing prevalence and severity of the clinical course of the disease. In this article, we review the most significant works and position papers published in Russia and abroad over the past 10 years, as well as the authors’ scientific and clinical experience, in order to identify key reasons behind the ineffective prevention of drug-induced osteonecrosis of the jaw in cancer patients and to suggests possible solutions. Questions concerning the legal protection of patients and clinicians in relation to this complication are discussed. Most recent achievements in the field of laboratory diagnostics and risk assessment of drug-induced osteonecrosis of the jaw in cancer patients, including the determination of bone metabolism markers, are presented. The following criteria for the safe use of bisphosphonates and denosumab in cancer patients were identified: dental screening; clinical and laboratory monitoring; individualizing drug dosage, duration and withdrawal regimens; application of an interdisciplinary approach.Keywords
This publication has 39 references indexed in Scilit:
- Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitionersBritish Dental Journal, 2017
- Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJJournal of Clinical Densitometry, 2017
- Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the JawJournal of Bone and Mineral Metabolism, 2016
- Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate TherapyJournal of Oral and Maxillofacial Surgery, 2016
- Cancel the denosumab holidayOsteoporosis International, 2016
- The effect of bisphosphonates on the endothelial differentiation of mesenchymal stem cellsScientific Reports, 2016
- Positionspapier zur medikamentenassoziierten Osteonekrose des Kiefers (MRONJ)Wiener Medizinische Wochenschrift, 2016
- A Case of Brain Abscess Caused by Medication-Related Osteonecrosis of the JawCase Reports in Dentistry, 2016
- Biochemical markers of bone metastasisAdvances in molecular oncology, 2015
- American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 UpdateJournal of Oral and Maxillofacial Surgery, 2014